| Literature DB >> 31142781 |
Samuel Le Goff1, Jean-Alix Barrat2, Laurent Chauvaud3, Yves-Marie Paulet3, Bleuenn Gueguen4, Douraied Ben Salem5.
Abstract
Gadolinium-based contrast agents (GBCAs), routinely used in magnetic resonance imaging (MRI), end up directly in coastal seawaters where gadolinium concentrations are now increasing. Because many aquatic species could be sensitive to this new pollution, we have evaluated the possibility of using shellfish to assess its importance. Gadolinium excesses recorded by scallop shells collected in Bay of Brest (Brittany, France) for more than 30 years do not reflect the overall consumption in GBCAs, but are largely controlled by one of them, the gadopentetate dimeglumine. Although its use has been greatly reduced in Europe over the last ten years, gadolinium excesses are still measured in shells. Thus, some gadolinium derived from other GBCAs is bioavailable and could have an impact on marine wildlife.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31142781 PMCID: PMC6541655 DOI: 10.1038/s41598-019-44539-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1REE patterns of shells normalised to Post Archean Australian Shale (PAAS)[19], from Japan[16] (a), North Sea[17] (b), Fuerteventura, Canary Islands (c), and Bay of Brest, France (d).
Figure 2REE patterns of scallop shells from Bay of Brest normalised to Post Archean Australian Shale (PAAS)[19]. The pattern of the local seawater is shown for comparison[21].
Figure 3Gadolinium anomalies (a: Gd/Gd*), gadolinium excesses (b: ΔGd) recorded by scallop shells sampled from 1960 to 2018 in Bay of Brest, and GBCA consumption in France recorded in the Medic’AM database[22] maintained by the CPAM (French Health Insurance agency) (c: total consumption and macrocyclic GBCAs, d: linear GBCAs).